The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates

In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including:Background information on the class of therapeutics known as ADCs, which have been on the market since 2000The number of headlines around ADCs lately, especially the standing ovation the data from Enhertu received at ASCO in 2022, making waves in breast cancer treatmentDeal structures and the BD side of ADCs, and their extended revenue generation potentialWhere the field is headed, in terms of clinical, BD and commercial standpointsRead and connect with our authors:  The Transactional Landscape Of ADCs: A Payday for Payloads